potassium channels Archives

BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials

May 31, 2024

A promising new BK channel opener, SPG601 from Spinogenix, is entering clinical trials for Fragile X syndrome. Learn about its potential to restore synaptic function and address core symptoms.

Reintroducing FMRP via Tat to Reduce Symptoms of Fragile X Syndrome

March 26, 2019

A FRAXA-funded team found that a shortened FMRP protein, delivered with a Tat “carrier,” restores brain signaling and improves behavior in Fragile X mice.

Novel Modulators of Potassium Channels to Treat Fragile X

January 2, 2019

FRAXA-funded Yale research showed disrupted Kv3.1 and Slack potassium channels impair neuronal timing in Fragile X. Published findings support Kv3.1 as a treatment target.

Newly Discovered Regulatory Pathways in Fragile X

October 31, 2017

Studies at Yale University and elsewhere are showing that FMRP plays a significant role in the regulation of potassium channels. Looking forward, potassium channel opener drugs could rescue some symptoms of Fragile X in humans.

Potassium Channel Modulators to Treat Fragile X

January 7, 2014

FRAXA-backed Yale discoveries tied Fragile X to Kv3.1/Slack channel defects—leading to a partnership with Autifony to develop targeted treatments.

Channelopathies: Altered Ion Channels in Fragile X Syndrome

September 15, 2011

With a $95,000 grant from FRAXA Research Foundation from 2010-2011, Dr. Daniel Johnston and Dr. Darrin Brager at the University of Texas at Austin investigated alterations in ion channels in Fragile X syndrome. They explored potential therapeutic effects of drugs which open and close these channels. Results published.

The Slack Potassium Ion channel is a Therapeutic Target for Fragile X

January 7, 2011

With $282,000 in funding from FRAXA Research Foundation, Dr. Leonard Kaczmarek and colleagues explored association of Slack channels with the Fragile X protein (FMRP).

BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials

Reintroducing FMRP via Tat to Reduce Symptoms of Fragile X Syndrome

Novel Modulators of Potassium Channels to Treat Fragile X

Newly Discovered Regulatory Pathways in Fragile X

Potassium Channel Modulators to Treat Fragile X

Channelopathies: Altered Ion Channels in Fragile X Syndrome

The Slack Potassium Ion channel is a Therapeutic Target for Fragile X

Support FRAXA

Get In Touch!

Explore Fragile X & Research

Get FRAXA Updates